Alan Crane

Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner focused on building and investing in healthcare companies. He has served as founder, chairman and/or CEO in building ight Polaris companies. Prior to Dyno, Alan founded Pandion Therapeutics, which raised a $58M series A and is focused on tissue-specific immunomodulation for autoimmune disorders and transplantation. Alan was also a founding investor in KSa Therapeutics, the leading company using CRISPR to discover the best therapeutic targets for disease intervention. The company has raised over $150M, including a crossover round. Alan's portfolio companies have collectively been involved in 9 IPOs and M&A exits. Previously, Alan was president and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with Novartis and raising $275 million. The first product from Momenta's pipeline achieved over $1B in sales during its first year. Alan received Enst& Young's Entrepreneur of the Year award for New England for this work. Prior to Polaris, Alan was senior VP of corporate development at Millennium Pharmaceuticals, where he was responsible for generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade@, which became the main basis of the company's $9B acquisition by Takeda. Alan earned a BA in biology, summa cum laude, an MA in biology, and an MBA from Harvard. He also spent two years studying towards an MD at Harvard Medical School.